Our Businesses

Innovative Medicines

We aspire to improve the lives of patients by ensuring access to quality cancer medicines through accelerated innovation and strong partnerships.

At Dr. Reddy’s, we are committed to expanding access to cutting-edge therapies by working closely with global innovators. Through strategic collaborations, we aim to bring novel treatments to India and other emerging markets, helping patients and healthcare providers address unmet needs and manage diseases better.

Aurigene Oncology

We are actively investing in advanced treatment platforms like Chimeric Antigen Receptor T (CAR-T) cell therapy, with efforts underway to build end-to-end capabilities in India supported by our licensing partners. Our wholly owned subsidiary, Aurigene Oncology Limited, is focused on discovering and advancing potentially best-in-class therapies for cancer and inflammatory diseases.

While our own pipeline is in the early stages of development, we remain focused on its long-term potential to address unmet needs. In parallel, we are accelerating access to innovative products through partnerships, especially in underserved therapeutic areas and/or markets. These efforts include voluntary licensing agreements for breakthrough treatments such as Lenacapavir. Through these initiatives, we aim to make the promise of innovation a reality for patients who need it most.

Learn more about Aurigene Oncology

Aurigene Oncology

Country Sites

Innovative Medicines

Aurigene Oncology

Invest in the future of medicine